Article info

Download PDFPDF
856 Routine baseline blood tests predicting pembrolizumab sensitivity in advanced high-grade serous ovarian cancer (AHGSOC) 1st line therapy: substudy from the NEOPEMBROV/GINECO (NCT03275506) randomized trial

Authors

Citation

Quesada S, Ray-Coquard I, Schiffler C, et al
856 Routine baseline blood tests predicting pembrolizumab sensitivity in advanced high-grade serous ovarian cancer (AHGSOC) 1st line therapy: substudy from the NEOPEMBROV/GINECO (NCT03275506) randomized trial

Publication history

  • First published March 10, 2024.
Online issue publication 
March 13, 2024

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.